Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer

Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer

Bibliographic Details
Main Authors: D.E. Magee, D.C. Cheung, A.E. Hird, S.S. Sridhar, N. Fallah-Rad, N.E. Fleshner, G.K. Kulkarni
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S266616832033651X

Internet

http://www.sciencedirect.com/science/article/pii/S266616832033651X

Similar Items